ladiratuzumab vedotin

{
  "id": "MLC-T-ONC-014707",
  "term": "ladiratuzumab vedotin",
  "field": "Oncology and biomedicine",
  "definition": "An antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody directed against the anti-solute carrier family 39 zinc transporter member 6 (SLC39A6; LIV-1; ZIP6) protein that is conjugated, via a protease-cleavable linker, to the cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. Upon administration and internalization by LIV-1-positive tumor cells, ladiratuzumab vedotin undergoes enzymatic cleavage to release MMAE into the cytosol. In turn, MMAE binds to and inhibits tubulin polymerization, which may result in G2/M phase cell cycle arrest and apoptosis in LIV-1-expressing tumor cells. LIV-1, a member of the zinc transporter family, is expressed in several types of solid tumors and plays a key role in tumor cell progression and metastasis. The linkage system in ladiratuzumab vedotin is highly stable in plasma, resulting in cytotoxic specificity against LIV-1-positive cells.",
  "synonyms": [
    "anti-LIV-1 monoclonal antibody-MMAE conjugate SGN-LIV1A",
    "anti-LIV-1 antibody-drug conjugate SGN-LIV1A"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/ladiratuzumab-vedotin/"
}